欢迎访问东方智库
会员登录 | 免费注册
讲师入驻通道
免费咨询热线：13810808675
Daniel Hoyer DanielHoyer,ProfessorofTheUniversityofMelbourne,Melbourne,Australia.ProfessorDanielHoyer,ChairandHeadoftheDepartmentofPharmacologyandTherapeutics,wasawardedtheMauriceRapportPrizeanddeliveredtheRapportPlenaryLectureatthe2016InternationalSocietyofSerotoninResearch(ISSR)Meeting.BeforejoiningtheUniversityofMelbournein2012,ProfessorHoyerhadalonganddistinguishedcareerinacademiaandindustry:afterhisPhDandDScfromStrasbourgUniversityandapostdoctorateattheUniversityofPennsylvaniaMedicalSchool,hejoinedthemultinationalpharmaceuticalcompanySandoz,thenNovartisinBasel.HeisanHonoraryProfessorialFellowattheFloreyInstituteofNeuroscienceandMentalHealthandanAdjunctProfessorintheDepartmentofChemicalPhysiologyattheScrippsResearchInstituteinLaJolla,California.InhiscurrentroleattheUniversityofMelbourne,ProfessorHoyer–incollaborationwithMonashUniversity’sProfessorWilliamCharman–ledtheestablishmentofProjectMercury,ahistoric$80millionpartnershipbetweenthetwouniversitiesandtheVictorianstategovernmenttoacceleratetr
Sun Choi（최선崔善） 최선교수는약학대학및대학원약학과소속교수로서컴퓨터를이용한약물설계및분자모델링분야의전문가이다.본교약대를졸업하고,미국StateUniversityofNewYorkatBuffalo에서의약화학전공으로박사학위를받았으며,미국Northwestern대학에서Post-doctoralfellow를하였다.그후2001년부터2005년까지컴퓨터를이용한약물설계분야의파이오니어적회사인미국Tripos본사에서molecularmodeler/computationalchemist로근무하며신약개발연구에기여하고,2005년부터본교교수로재직중이다.최선교수는질병에중요한효소,GPCR,이온채널등을대상으로하는약물설계와신약개발을위한다양한연구프로젝트들을진행하고있다.컴퓨터를이용한약물설계와화학정보학및계산의약화학등이통합된첨단기술을이용하여암,바이러스,심혈관계질환,골다공증등다양한질환에대한약물개발전략을세우고,지식기반의활성물질검색및구조-활성상관관계분석,활성부위와약리작용단분석,화합물라이브러리와신물질설계,도킹등을이용한가상탐색,효능예측,HTSdata분석,hit/선도물질의최적화,타겟단백질과리간드의상호작용및작용기전에대한연구를수행하고있다.또한,단백질다이나믹스와알로스테리규명을위한multi-scalesimulation도활발히연구하고있다.최선교수는이러한연구결과들을,등저명한국제학술지에50여편의논문으로발표하였고,18thEuroQSARSymposium'DiscoveryInformatics&DrugDesign'에서BestPosterPresentationAward와EFMC'XXthInternationalSymposiumonMedicinalChemistry'에서Wiley-VCHChemMedChemPosterPrize등을수상하였다.최선교수의연구실은2011년9월부터한국연구재단의지원을받아중견연구자도약연구과제로'단백질상호작용의HotSpot과알로스테릭제어기전규명을위한멀티스케일시뮬레이션연구및알로스테릭저해제기반연구'를수행하고있으며,미래창조과학부지정국가선도연구실(NationalLeadingResearchLaboratory;NLRL)로서다양한신약개발연구를진행하고있다.
热点文章
-
02-18 / (4271)
-
02-29 / (2717)
联系我们
微信咨询
微信扫一扫
